Paradoxical results in urine drug testing for 6-acetylmorphine and total opiates: Implications for best analytical strategy

Journal of Analytical Toxicology

Volumn 30, Issue 2, 2006, Pages 73-79

  Beck, Olof ^a   Böttcher, Michael ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Arztpraxis fur Medizinische Mikrobiologie und Labordiagnostik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHINE 6 ACETATE; OPIATE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG ABUSE; EVALUATION; FEMALE; GAS CHROMATOGRAPHY; HEROIN DEPENDENCE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; SUBSTITUTION REACTION; URINALYSIS;

EID: 33644980285     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/30.2.73     Document Type: Article

References (33)

1. F. Musshoff, J. Trafkowski, and B. Madea. Validated assay for the determination of markers of illicit heroin in urine samples for the control of patients in a heroin prescription program. J. Chromatogr. B 811: 47-52 (2004).
2. R.A. Braithwaite, D.R. Jarvie, P.S.B. Minty, D. Simpson, and B. Widdop. Screening for drugs of abuse. I: Opiates, amphetamines and cocaine. Ann. Clin. Biochem. 32: 123-153 (1995).
3. Department of Health and Human Services. Mandatory guidelines for federal workplace drug testing programs. Fed. Regist. 69: 19644-19673 (2004).
4. B.D. Paul, E.T. Shimomura, and M.L. Smith. A practical approach to determine cutoff concentrations for opiate testing with simultaneous detection of codeine, morphine, and 6-acetylmorphine in urine. Clin. Chem. 45: 510-519 (1999).
5. J.M. Holler, T.Z. Bosy, K.L. Klette, R. Wiegand, J. Jemionek, and A. Jacobs. Comparison of the Microgenics CEDIA heroin metabolite (6-AM) and the Roche Abuscreen ONLINE opiate immunoassays for the detection of heroin use in forensic urine samples. J. Anal. Toxicol. 28: 489-493 (2004).
6. E.J. Cone, P. Welch, J.M. Mitchell, and B.D. Paul. Forensic drug tresting for opiates. I. Detection of 6-acetylmorphine in urine as an indicator of recent heroin exposure; drug assay considerations and detection times. J. Anal. Toxicol. 15: 1-7 (1991).
7. C. George, S. George, and S. Parmar. Application of the CEDIA 6-MAM assay to routine drugs-of-abuse screening. J. Anal. Toxicol. 26: 233-235 (2002).
8. L.R. Glass, S.T. Ingalls, C.L. Schilling, and C.L. Hoppel. Atypical urinary opiate excretion pattern. J. Anal. Toxicol. 21: 509-514 (1997).
9. M. von Euler, T. Villen, J.O. Svensson, and L. Stahle. Interpretation of the presence of 6-monoacetylmorphine in the absence of morphine-3-glucuronide in urine samples: evidence of heroin abuse. Ther. Drug Monit. 25: 645-648 (2003).
10. N. Fortner, D. Crook, R. Turk, and A. Wasnyn. Unusual drug test results from known heroin users. In the proceedings of The 42nd TIAFT Conference. Washington, D.C., August 2004.
11. DIN: Nachueis-, Erfassugs-, und Beslimmungsgoenze, Beuth Verlag, Berlin, Germany, 1994.
12. M. Kolb, A. Bahr, S. Hippich, and W. Schulz. Calculation of the detection limit, identification limit, and determination limit according to DIN 32645 with the aid of a computer program. Acta Hydrochim. Hydrobiol. 21: 308-311 (1993).
13. Z. Lin, P. Lafolie, and O. Beck. Evaluation of analytical procedures for urinary codeine and morphine measurements. J. Anal. Toxicol. 18: 129-133 (1994).
14. G. Skopp, B. Ganssmann, E.J. Cone, and R. Aderjan. Plasma concentrations of heroin and morphine-related metabolites after intranasal and intramuscular administration. J. Anal. Toxicol. 21: 105-111 (1997)
15. E. Gyr, R. Brenneisen, D. Bourquin, T. Lehmann, D. Vonlanthen, and I. Hug. Pharmacodynamics and pharmacokinetics of intravenously, orally and rectally administered diacetylmorphine in opioid dependents, a two-patient pilot study within a heroin-assisted treatment program. Int. J. Clin. Pharmacol. Ther. 38: 486-491 (2000).
16. F. Girardin, K.M. Rentsch, M.A. Schwab, M. Maggiorini, C. Pauli-Magnus, G.D. Kullak-Ublick, P.J. Meier, and K. Fattinger. Pharmacokinetics of high doses of intramuscular and oral heroin in narcotic addicts. Clin. Pharmacol. Ther. 74: 341-352 (2003).
17. M.L. Smith, E.T. Shimomura, J. Summers, B.D. Paul, A.J. Jenkins, W.D. Darwin, and E.J. Cone. Urinary excretion profiles for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin. J. Anal. Toxicol. 25: 504-514 (2001).
18. C. Staub, M. Marset, A. Mino, and P. Mangin. Detection of acetylcodeine in urine as an indicator of illicit heroin use: method validation and results of a pilot study. Clin. Chem. 47: 301-307 (2001).
19. A.C. Spanbauer, S. Casseday, D. Davoudzadeh, K.L. Preston, and M.A. Huestis. Detection of opiate use in a methadone maintenance treatment population with the CEDIA 6-acetylmorphine and CEDIA DAU opiate assays. J. Anal. Toxicol. 25: 515-519 (2001).
20. A.W. Jones. Heroin use by motorists in Sweden confirmed by analysis of 6-acetylmorphine in urine. J. Anal. Toxicol. 25: 353-355 (2001).
21. M.R. Hutchinson and A.A. Somogyi. Diacetylmorphine degradation to 6-monoacetylmorphine and morphine in cell culture: implications for in vitro studies. Eur. J. Pharmacol. 453: 27-32 (2002).
22. S. Bencharit, C.L. Morton, Y. Xue, P.M. Potter, and M.R. Redinbo. Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme. Nat. Struct. Biol. 10: 349-356 (2003).
23. S. Matsh, M. Xiao, J. Yu, R. Ahluwalia, M. Minton, R.R. Freimuth, P.Y. Kwok, and H.L. McLeod. Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics 84: 661-668 (2004).
24. M. Holthe, T.N. Rakvag, P. Klepstad, J.R. Idle, S. Kaasa, H.E. Krokan, and F. Skorpen. Sequence variations in the UDP-glucuronyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics 3: 17-26 (2003).
25. T.K.L. Kiang, M.H.H. Ensom, and T.K.H. Chang. UDP- glucuronysyltransferases and clinical drug-drug interactions. Pharmacol. Ther. 106: 97-132 (2005).
26. A. Fugelstad, J. Ahlner, L. Brandt, G. Ceder, S. Eksborg, J. Rajs, and O. Beck. Use of morphine and 6-monoacetylmorphine in blood for the evaluation of possible risk factors for sudden death in 192 heroin users. Addiction 98: 463-470 (2003).
27. S. Darke, J. Ross, D. Zador, and S. Sunjic. Heroin-related deaths in New South Wales, Australia, 1992-1996. Drug Alcohol Dep. 60: 141-150 (2000).
28. P.O. Coffin, S. Galea, J. Ahern, A.C. Leon, D. Vlahov, and K. Tardiff. Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990-98. Addiction 98: 739-747 (2003).
29. A. Polettini, A. Groppi, and M. Montagna. The role of alcohol abuse in the etiology of heroin-related deaths. Evidence for pharmacokinetic interactions between heroin and alcohol. J. Anal. Toxicol. 23: 570-576 (1999).
30. M.M. Kushnir, D.K. Crockett, G. Nelson, and F.M. Urry. Comparison of four derivatizing reagents for 6-acetylmorphine GC-MS analysis. J. Anal. Toxicol. 23: 262-269 (1999).
31. A.J. Jenkins, E.S. Lavins, and A. Snyder. Evaluation of the Cedia heroin metabolite (6-AM) immunoassay with urine specimens from criminal justice drug-testing program. J. Anal. Toxicol. 28: 201-204 (2005).
32. F. Pragst, K. Spiegel, U. Leuschner, and A. Hager. Detection of 6-acetylmorphine in vitreous humor and cerebrospinal fluid - comparison with urinary analysis for proving heroin administration in opiate fatalities. J. Anal. Toxicol. 23: 168-172 (1999).
33. K.A. Moore, J. Addison, B. Levine, and J.E. Smialek. Applicability of opiate cutoffs to opiate intoxication cases. J. Anal. Toxicol. 25: 657-658 (2001).